NCT00498836View on ClinicalTrials.gov

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Malignant Melanoma
Interventions
DRUG

CP-4055

CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion

DRUG

Sorafenib (Nexavar)

Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing

Trial Locations (6)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

78229

Cancer Therapy and Research Center, Institute for Drug Development, San Antonio

NO-0310

The Norwegian Radium Hospital, Oslo

SE-221 85

Lund University Hospital, Lund

Unknown

Umeå University Hospital, Umeå

SE-751 85

Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

Clavis Pharma
All Listed Sponsors
lead

Clavis Pharma

INDUSTRY

NCT00498836 - Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter